

such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.--

REMARKS

The specification has been amended herein to insert Applicant's claim of priority, and to insert the Abstract, originally included in the first page of the International Application, as the last page of the specification. No new matter has been added.

The priority claim was already set forth in the cover sheet that accompanied the patent application and in the cover sheet of the PCT application that was submitted with the application as filed.

If any matters remain to be discussed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

**Marked-up Version of Amended Specification
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

On page 1, line 4, please insert the following paragraph:

PRIORITY CLAIM

This is a § 371 U.S. national stage of PCT/US00/09979, filed April 13, 2000, which was published in English under PCT Article 21(2), and claims the benefit of U.S. Application No. 60/130,434, filed April 21, 1999.

Please add the Abstract, as shown on the attached marked-up version of page 54 of the specification.

Abstract

**UTEROGLOBIN IN THE TREATMENT OF
IgA MEDIATED AUTOIMMUNE DISORDERS**

5

Uteroglobin has been discovered to prevent IgA mediated diseases, such
as IgA nephropathy, by preventing the deposition of IgA-Fibronectin
immunocomplexes in tissues such as the renal glomeruli. The invention therefore
includes methods of treating such diseases by administering therapeutically
10 effective amounts of uteroglobin (and variants or mimetics) to prevent or improve
the IgA mediated condition. Transgenic uteroglobin knockout animals, and
animals in which uteroglobin-protein expression is reduced by antisense
technology, also provide systems for studying IgA mediated diseases, and
screening for appropriate treatments.

15